Navigation Links
Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
Date:2/16/2011

SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the completion of a public offering of 6,900,000 shares of its common stock, including 900,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. The shares were sold at a public offering price of $11.25 per share, resulting in aggregate gross proceeds to Optimer of $77.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Optimer.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Jefferies & Company, Inc. acted as the sole book-running manager for the offering. Baird, Canaccord Genuity Inc., JMP Securities, Needham & Company, LLC, and ThinkEquity LLC acted as co-managers for the offering.  

Optimer anticipates using the net proceeds from the offering to prepare for the potential commercial launch of fidaxomicin in the United States, if approved, as well as for research and development activities, potential in-licenses or acquisitions, working capital and other general corporate purposes.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission (SEC) and is effective. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340 and at Prospectus_Department@Jefferies.
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
3. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
4. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
5. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
6. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
9. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
11. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, a ... technologies, today announced that it has been selected as ... Industry Association,s 2014 Awards for Excellence competition ... an independent panel of judges from SCORE (Counselors to ... winners will be honored at a gala event to ...
(Date:8/27/2014)... BIOEQUA, an innovative line of skin care ... handheld spray, has made its EQUA ESSENTIAL line available ... brand began with an unexpected discovery in an emergency ... that the application of nanospray technology allowed for liquid ... to skin's basal layer. This resulted in immediate absorption ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... Supply Report, “Consolidation continues to reshape the look and ... in nutrition. Consumer demand for higher-quality ingredients will push ... the North American market have experienced strong market growth ... and ethical attributes in their food and cosmetics to ...
(Date:8/27/2014)... WriteResult, LLC – a premier provider of ... superiority when it comes to meeting the needs of ... of their most recent study closeout on-time and with ... digital writing platform to collect Patient Reported Outcomes electronically ... drew data from a number of assessments including the ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Washington, D.C. -- The biological pathway that powers ... nanotech devices, releasing drugs or performing mechanical functions inside ... Society for Cell Biologys 47th Annual meeting. , ... Animal Health may be the first demonstration of how ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and ... program to develop an IgA protease for,treating IgA ... IgA,complexes, the deposition of which causes IgA nephropathy, ... has executed a research,and option agreement with IGAN ...
... Vicus Therapeutics, LLC, an,oncology-focused, clinical-stage biopharmaceutical company, ... present at the BMO Capital,Markets Focus on Healthcare ... 2007 at 1:30 p.m. ET at the Millennium ... Therapeutics, Vicus Therapeutics is a privately-held, biopharmaceutical ...
Cached Biology Technology:Tethered to chip, energy supply that drives sperm could power 'nanobot' 2BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 2BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 3BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease 4
(Date:8/27/2014)... of Utah biologist agan Sekercioglu, who campaigns to save ... highest science prize, which is similar to the U.S. ... researchers picked for 2014 the top awards by TUBITAK, ... researchers won the Science Award and two including ... to the Science Award but for scientists who are ...
(Date:8/27/2014)... are often depicted as giant, frightening beasts. But every ... of a rock slab containing fossils of 24 very ... a group of hatchlings overseen by a caretaker, according ... , Penn,s Brandon P. Hedrick and Peter Dodson led ... of Natural History, where the specimen is held. Hedrick ...
(Date:8/27/2014)... (June, 2014) Outstanding basic research, a growing ... dedication to patient care have earned the Herbert ... Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 ... National Cancer Institute (NCI). The grant renews the ... Comprehensive Cancer Centers in New York City and ...
Breaking Biology News(10 mins):University of Utah biologist wins Turkey's top science prize 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... creating a better way to see molecules at work in ... Learning and Memory and the MIT Department of Chemistry are ... also help further understanding of how synapses go awry in ... study will appear in the Oct. 7 issue of ...
... survival rates. Yet, one of the deadliest cancers in ... detect in its early stages. Now, researchers have ... shining diffuse light on cells swabbed from patients, cheeks. ... partial wave spectroscopic (PWS) microscopy--was able to differentiate individuals ...
... make life tougher for farmers and ranchers who live in ... why not turn the plants into fuel and make some ... alone could supply biomass far into the future, according to ... to fuel is an intriguing idea that,s being investigated by ...
Cached Biology News:MIT researchers develop a better way to see molecules at work in living brain cells 2Cheek swab may detect lung cancer 2Cheek swab may detect lung cancer 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
... A direct, simple approach to ... well surface of an EIA ... maintains its integrity and availability ... dry, room temperature conditions ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
... lyophilization stabilizer is designed to stabilize ... for long-term storage. There are ... It is a convenient 10 ... and is superior to other traditional ...
... The Techne TC-512 is the only Gradient thermal ... at the touch of a screen. ,Wide ... on the market, with an amazing range of,30C. ... , TouchScreen - The Touchgene Gradient incorporates ...
Biology Products: